30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Kamal Adawi

Track

Insider profile

Currently holds a position at Exagen Inc

Performance

Overall performance
2.7
Performance over holding periods
2.7
30 days 90 days 120 days
Average return 9% 8.2% 15.1%
Success rate 65% 68% 82%
Transactions
5 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Financial Officer Exagen Inc June 1, 2017 -
Kamal Adawi's trades of Exagen Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-10-08 2024-10-08
US Exagen Inc (XGN)
PrS Proposed sale
9,307
452.80
US$3,569,929 		9,307 452.80 US$3,569,929
2024-08-09 2024-08-09
US Exagen Inc (XGN)
PrS Proposed sale
22,696
203.25
US$4,585,246 		22,696 203.25 US$4,585,246
2024-03-06 2024-03-04
US Exagen Inc (XGN)
S Sale
8,286 -41.5%
481.63
US$506,544 		8,286 -41.5% 481.63 US$506,544
2024-03-06 2024-03-04
US Exagen Inc (XGN)
S Sale
9,297 -3.6%
1.91
US$17,747 		9,297 -3.6% 1.91 US$17,747
2024-02-08 2024-02-06
US Exagen Inc (XGN)
S Sale
6,738 -3.6%
1.95
US$13,133 		6,738 -3.6% 1.95 US$13,133
2023-03-03 2023-03-02
US Exagen Inc (XGN)
S Sale
3,667 -1.9%
2.30
US$8,432 		3,667 -1.9% 2.30 US$8,432
2023-02-10 2023-02-08
US Exagen Inc (XGN)
S Sale
5,821 -6.0%
2.69
US$15,671 		5,821 -6.0% 2.69 US$15,671